Pasithea Therapeutics Corp. - Common Stock (KTTA)
Frequently Asked Questions About Pasithea Therapeutics Corp. - Common Stock (KTTA)
Has Pasithea Therapeutics completed any clinical trials?
Yes, Pasithea Therapeutics has initiated and completed several clinical trials aimed at testing the safety and efficacy of its drug candidates. The results from these trials contribute to the ongoing development of its product pipeline.
How can investors learn more about Pasithea Therapeutics?
Investors can learn more about Pasithea Therapeutics by visiting their official website, reviewing their SEC filings, and following their press releases and investor presentations for updates on corporate developments and financial performance.
How does Pasithea Therapeutics define success?
Pasithea Therapeutics defines success not only through achieving clinical milestones and regulatory approvals but also by making a positive impact on patients' lives and advancing the field of mental health treatment.
How does Pasithea Therapeutics ensure patient safety in clinical trials?
Pasithea Therapeutics ensures patient safety in clinical trials by adhering to strict regulatory guidelines, conducting thorough risk assessments, and monitoring participants closely throughout the study to identify and manage any adverse events.
Is Pasithea involved in any partnerships or collaborations?
Yes, Pasithea Therapeutics actively seeks strategic partnerships and collaborations with academic institutions, research organizations, and other companies in the biopharmaceutical industry to enhance its research capabilities and expedite drug development.
Is Pasithea Therapeutics publicly traded?
Yes, Pasithea Therapeutics Corp. is publicly traded on the Nasdaq under the ticker symbol 'KTTA', providing investors the opportunity to participate in its growth.
What are the potential benefits of Pasithea's therapies?
The potential benefits of Pasithea Therapeutics' therapies include improved efficacy in managing symptoms of mental health disorders, fewer side effects compared to traditional treatments, and enhanced overall quality of life for patients.
What are the primary areas of focus for Pasithea Therapeutics?
The primary areas of focus for Pasithea Therapeutics include developing treatments for psychiatric disorders such as depression and anxiety, as well as neurological disorders like Alzheimer's disease.
What challenges does Pasithea Therapeutics face in the biopharmaceutical industry?
Like many biopharmaceutical companies, Pasithea Therapeutics faces challenges such as regulatory hurdles, competition in drug development, and the need for substantial funding to support ongoing research and clinical trials.
What does Pasithea Therapeutics Corp. do?
Pasithea Therapeutics Corp. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for the treatment of psychiatric and neurological disorders. The company is committed to addressing unmet medical needs in mental health through its research and development efforts.
What is Pasithea's lead product candidate?
Pasithea's lead product candidate is a novel pharmacological agent aimed at treating treatment-resistant depression, targeting pathways in the brain that are believed to be involved in mood regulation.
What is the company's approach to research and development?
Pasithea Therapeutics employs a rigorous approach to research and development, utilizing cutting-edge scientific methods and technologies to discover and develop new therapies, including leveraging insights from emerging fields like neuroscience and biotechnology.
What is the future outlook for Pasithea Therapeutics?
The future outlook for Pasithea Therapeutics appears promising as the company continues to advance its clinical programs and expand its portfolio of drug candidates, particularly in the growing market for mental health treatments.
What is the mission of Pasithea Therapeutics?
The mission of Pasithea Therapeutics is to transform mental healthcare by advancing innovative and effective treatments for patients suffering from psychiatric and neurological disorders, thereby improving their quality of life.
What is the significance of the name 'Pasithea'?
The name 'Pasithea' is derived from Greek mythology; Pasithea is the goddess of relaxation and hallucination, symbolizing the company's focus on addressing mental health issues and promoting patient well-being.
When was Pasithea Therapeutics Corp. founded?
Pasithea Therapeutics Corp. was founded in 2020, aiming to pioneer novel treatment options in the growing field of psychopharmacology.
Where is Pasithea Therapeutics Corp. headquartered?
Pasithea Therapeutics Corp. is headquartered in Miami, Florida, where it operates its main offices and clinical trial management.
Who are Pasithea Therapeutics' target patients?
Pasithea Therapeutics' target patients include individuals suffering from psychiatric and neurological disorders, particularly those who have not responded to existing treatment options, representing a significant unmet need in healthcare.
Who are the key executives at Pasithea Therapeutics?
The key executives at Pasithea Therapeutics include a team of experienced professionals from diverse backgrounds in biopharmaceuticals, clinical research, and business development, leading the company’s strategic vision and operations.
What is the current price of Pasithea Therapeutics Corp. - Common Stock?
The current price of Pasithea Therapeutics Corp. - Common Stock is 1.190
When was Pasithea Therapeutics Corp. - Common Stock last traded?
The last trade of Pasithea Therapeutics Corp. - Common Stock was at 4:00 pm EDT on April 2nd, 2025